natgillin/translations-raw huggingface dataset:
It is possible to switch directly from oral administration to infusion and the other way around.
Võimalik on üleminek suukaudselt manustamiselt veenisisesele ja vastupidi.
It is postulated that these actions protect endothelial cells.
On kindlaks tehtud, et kõik need toimed kaitsevad endoteelirakke.
It is preferable not to take this medicine during pregnancy .
Seda ravimit ei ole soovitatav võtta raseduse ajal.
It is preferable not to take this medicine during pregnancy.
Seda ravimit ei ole soovitatav võtta kasutada raseduse ajal.
It is preferable not to take this medicine during pregnancy.
Seda ravimit ei ole soovitatav võtta raseduse ajal.
It is preferable not to take this product during pregnancy..
Seda ravimit ei ole soovitatav võtta kasutada raseduse j a rinnaga toitmise ajal.
It is preferable not to use this product during pregnancy and breast-feeding.
Seda ravimit on parem mitte kasutada raseduse ja rinnaga toitmise ajal.
It is preferable to avoid the use of BRINAVESS during pregnancy.
Raseduse ajal on parem BRINAVESS’i kasutamisest hoiduda.
It is preferable to avoid the use of Cosentyx in pregnancy.
Cosentyx’i kasutamist raseduse ajal on soovitatav vältida.
It is preferable to avoid the use of Stelara in pregnancy.
Raseduse ajal on soovitatav Stelara kasutamist vältida.
It is preferable to avoid the use of Taltz in pregnancy.
Raseduse ajal on eelistatav Taltz’i kasutamisest hoiduda.
It is preferable to take your medicine at the same time each day.
Eelistatult võtta oma ravimit iga päev samal kellaajal.
It is prepared from the highly purified virus-like particles (VLPs) of the major capsid L1 protein from the same four HPV types (6, 11, 16, 18) in qHPV vaccine Gardasil or Silgard and from 5 additional HPV types (31, 33, 45, 52, 58).
See on valmistatud qHPV vaktsiini Gardasili või Silgardi nelja sama HPV tüübi (6, 11, 16 ja 18) peamise kapsiidivalgu L1 kõrgpuhastatud viiruslaadsetest partiklitest (virus-like particle, VLP) ja viiest täiendavast HPV tüübist (31, 33, 45, 52, 58).
It is presented as 15- or 50-litre steel cylinders containing compressed oxygen gas.
Toodet turustatakse 15- või 50-liitristes terasballoonides, mis sisaldavad kokkusurutud gaasilist hapnikku.
It is printed on the labels and on the carton.
See on trükitud etikettidele ning välispakendile.
It is produced by a method known as ‘recombinant DNA technology’: it is made by a bacterium into which a gene (DNA) has been introduced, which makes it able to produce anakinra.
Kinereti valmistatakse rekombinant-DNA-tehnika abil: seda toodavad bakterid, millele on lisatud anakinra teket võimaldav geen (DNA).
It is produced by a method known as ‘recombinant DNA technology’: it is made by a cell that has received a gene (DNA), which makes it able to produce epoetin theta.
Teetaepoetiini valmistatakse rekombinant-DNA-tehnika abil: seda toodab rakk, millele on lisatud teetaepoetiini teket võimaldav geen (DNA).
It is produced by a method known as ‘recombinant DNA technology’: it is made by a cell that has received a gene (DNA), which makes it able to produce epoetin zeta.
Seda toodetakse rekombinant-DNA-tehnika abil: seda toodab rakk, millele on lisatud dzeetaepoetiini teket võimaldav geen (DNA).
It is produced by a method known as ‘recombinant DNA technology’: it is made by a cell that has received a gene (DNA), which makes it able to produce epoetin zeta.
Seda valmistatakse rekombinant-DNA-tehnika abil: seda toodab rakk, millele on lisatud dzeetaepoetiini teket võimaldav geen (DNA).
It is produced by a method known as ‘recombinant DNA technology’: the enzyme is made by cells into which a gene (DNA) has been introduced that makes them able to produce laronidase.
Seda valmistatakse rekombinant-DNA-tehnika abil: ensüümi toodavad rakud, millesse on viidud laronidaasi teket võimaldav geen (DNA).
It is produced by a method known as ‘recombinant DNA technology’: the hormone is made by a bacterium that has received a gene (DNA) that makes it able to produce it.
Seda toodetakse rekombinant-DNA-tehnikana tuntud meetodil: hormooni toodab bakter, millele on lisatud selle teket võimaldav geen (DNA).
It is produced by a method known as ‘recombinant DNA technology’: the hormone is made by a bacterium which has received a gene (DNA) that makes it able to produce it.
Seda toodetakse rekombinant-DNA-tehnika abil: hormoon tekib bakteris, mis on saanud selle tootmist võimaldava geeni (DNA).
It is produced by a method known as ‘recombinant DNA technology’: the hormone is made by a yeast that has received a gene (DNA) that makes it able to produce somatropin.
Seda valmistatakse rekombinant-DNA- tehnika abil: hormooni toodab pärm, millele on lisatud somatropiini teket võimaldav geen (DNA).
It is produced by a method known as ‘recombinant DNA technology’: the hormone is made by bacteria into which a gene (DNA) has been introduced that makes them able to produce somatropin.
Seda toodetakse rekombinant-DNA- tehnika abil: somatropiini toodab bakter, millele on lisatud somatropiini teket võimaldav geen (DNA).
It is produced by a method known as ‘recombinant DNA technology’: the hormone is made by yeast cells into which a gene (DNA) has been introduced that makes them able to produce it.
Seda toodetakse rekombinant-DNA-tehnika abil: hormooni toodab pärmirakk, millesse on lisatud somatropiini tootmist võimaldav geen (DNA).
It is produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells, and prepared without the addition of any human or animal derived protein in the cell culture process, purification or final formulation.
Seda toodetakse rekombinantse DNA tehnoloogia abil hiina hamstri munasarja rakkudes, lisamata ühtegi inim- või loomse päritoluga proteiini rakukultiveerimise ja puhastamise protsessi käigus või lõplikku koostisesse.
It is produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells, and prepared without the addition of any human – or animal derived protein in the cell culture process, purification or final formulation.
Seda toodetakse rekombinantse DNA tehnoloogia abil hiina hamstri munasarja rakkudes, lisamata ühtegi inim- või loomse päritoluga proteiini rakukultiveerimise ja puhastamise protsessi käigus või lõplikku koostisesse.
It is provided in a 100 ml brown glass bottle with a white, child resistant screw cap.
Ravim on valge lastekindla keeratava korgiga 100 ml pruunis klaaspudelis.
It is provided in a ready-to-use pre-filled syringe, containing a single dose of 0.5 ml for injection.
Seda turustatakse kasutamisvalmis eeltäidetud süstlina, mis sisaldab ühte 0,5 ml süsteannust.
It is provided in: a ready-to-use syringe, containing a single dose of 0.5 ml for injection;
Seda turustatakse: kasutamisvalmis süstelina, mis sisaldab ühte 0,5 ml süsteannust;
It is provided with a 1 ml pre-filled glass syringe of solvent for reconstitution (water for injections) and one needle.
Lisatud on 1 ml lahustiga (süsteveega) klaasist süstel süstelahuse valmistamiseks ja üks nõel.
It is prudent to reserve the fluoroquinolones for the treatment of clinical conditions that have responded poorly, or are expected to respond poorly, to other classes of antibiotic.
Mõistlik on fluorokinoloone kasutada vaid siis, kui haigus ei allu või tõenäoliselt ei allu teistele antibiootikumidele.
It is prudent to reserve third generation cephalosporins for the treatment of clinical conditions, which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials or first generation cephalosporins.
Kolmanda põlvakonna tsefalosporiine on mõistlik kasutada selliste kliiniliste seisundite raviks, mille puhul ei ole andnud piisavat tulemust või mille puhul oletatakse ebapiisavat tulemust teiste antimikrobiaalsete ravimitega või esimese põlvkonna tsefalosporiinidega.
It is quite normal to have a number of courses of Ratiograstim treatment.
Tavaline on Ratiograstim-ravi korduv saamine.
It is quite normal to have a number of courses of Tevagrastim treatment.
Tavaline on Tevagrastim-ravi korduv saamine.
It is quite normal to have a number of courses of treatment with Accofil.
On üsna tavaline, et Accofil ’iga tehakse mitu ravikuuri.
It is quite normal to have a number of courses of treatment with Accofil.
On üsna tavaline, et Accofil’iga tehakse mitu ravikuuri.
It is rare; if it happens, it usually develops after a few months of treatment.
Seda esineb harva; tavaliselt tekib see pärast mõned kuud kestnud ravi.
It is ready to use - you do not need to mix it with anything.
Korki ega tuubi ei ole vaja keerata.
It is ready to use - you do not need to mix it with anything.
Vaktsiin on kasutusvalmis – seda ei pea millegagi segama.
It is recommended not to chew, crush or split the tablets because it may change the level of medicine in your body.
Tablette ei ole soovitatav närida, purustada ega poolitada, sest see võib muuta ravimi sisaldust teie organismis.
It is recommended not to repeat ear cleaning until 21 days after the second administration of the product.
Kõrva ei ole soovitatav puhastada uuesti enne, kui on möödunud 21 päeva ravimi teistkordsest manustamisest.
It is recommended not to use Luveris if you have any condition that usually makes a normal pregnancy impossible, such as ovaries that do not work because of a condition called primary ovarian failure, or malformations of sexual organs.
Luveris’t ei ole soovitatav kasutada, kui teil esineb mõni seisund, mis muudab tavaliselt normaalse raseduse võimatuks, nagu primaarse munasarjade puudulikkuse tõttu mittetalitlevad munasarjad või suguelundite väärarengud.
It is recommended that 0.5 mg/kg intravenous busulfan be administered every 6 hours on two consecutive days starting three days before administration of Strimvelis.
Soovitatav on manustada 0,5 mg/kg intravenoosset busulfaani iga 6 tunni järel kahel järjestikusel päeval, alustades kolm päeva enne Strimvelis’e manustamist.
It is recommended that a diet and exercise programme is started before beginning treatment with alli.
Dieedi ja kehalise koormuse programmiga tuleb algust teha juba enne alli’ga ravi alustamist.
It is recommended that a fourth dose be given as a ‘booster’ at least six months after the third dose, preferably when the child is between 12 and 15 months of age.
Vähemalt 6 kuu pärast, kui laps on 12–15-kuune, soovitatakse manustada kolmanda annuse järel tugevdav neljas annus.
It is recommended that a fourth dose be given as a ‘booster’ at least six months after the third dose.
Vähemalt 6 kuu möödudes 3. annuse manustamisest soovitatakse anda tugevdav 4. annus.
It is recommended that a healthcare professional trains patients in the proper technique for self-administering subcutaneous injections using the pre-filled pen.
Tervishoiutöötaja peaks õpetama patsienti enesele õigesti pen-süstli abil subkutaanset süsti manustama.
It is recommended that a healthcare professional trains patients in the proper technique for self-administering subcutaneous injections using the pre-filled syringe.
Tervishoiutöötaja peaks õpetama patsienti enesele õigesti süstli abil subkutaanset süsti manustama.
It is recommended that a neurological examination be performed in patients prior to starting BLINCYTO therapy and that patients be clinically monitored for signs and symptoms of neurologic events (e.g. writing test).
Enne ravi alustamist BLINCYTO’ga on soovitatav neuroloogiline läbivaatus ning ravi ajal on soovitatav patsiente kliiniliselt jälgida neuroloogiliste juhtude nähtude ja sümptomite suhtes (nt kirjutuskatse).
It is recommended that a standard 20 ml (non-automated) syringe be used to ensure that the exact amount (19.0 ml) of Water for Injections or of 9 mg/ml (0.9%) Sodium Chloride for Infusion is dispensed.
Lahustamiseks on soovitatav kasutada standardset 20 ml (mitteautomaatset) süstalt, et kindlustada kogu süstevee (19 ml) või 0,9%-lise (9 mg/ml) naatriumkloriidi infusioonilahuse mahtumist süstlasse.
It is recommended that a standard 20 ml (non-automated) syringe be used to ensure that the exact amount (19.0 ml) of water for injections or of sodium chloride 9 mg/ml (0.9%) solution for injection is dispensed.
Lahustamiseks on soovitatav kasutada standardset 20 ml (mitteautomaatset) süstalt, et kindlustada kogu süstevee (19,0 ml) või 9 mg/ml (0,9%) naatriumkloriidi süstelahuse mahtumise süstlasse.
It is recommended that a test dose of 5-10 mg be administered subcutaneously one week prior to initiation of therapy, in order to detect idiosyncratic adverse effects.
Üks nädal enne ravi alustamist on soovitatav manustada subkutaanselt prooviannus 5-10 mg, et teha kindlaks idiosünkraatilised kõrvaltoimed.
It is recommended that a test for FeLV antigenaemia be carried out prior to vaccination.
. Enne vaktsineerimist on soovitav teha testid FeLV antigeenide esinemisele veres.
It is recommended that a third dose be given as a ‘booster’ at least two months after the second dose, during the child’s second year of life.
Vähemalt 2 kuu möödudes 2. annuse manustamisest soovitatakse anda teisel eluaastal tugevdav 3. annus.
It is recommended that after reconstitution the colourless, clear to opalescent solution should be used immediately.
Saadud värvitu ja selge või kergelt küütlev lahus tuleks kasutada koheselt.
It is recommended that Aivlosin is first mixed into 10 kg of the feeding stuff, followed by the rest of the feeding stuff and mixed well.
Aivlosin soovitatakse kõigepealt segada 10 kg söödaga, mis seejärel tuleb lisada tervele söödakogusele ja hästi läbi segada.
It is recommended that all children who receive the first dose of Synflorix complete the full vaccination course.
Kõikidele lastele, kes saavad 1. annuse Synflorixi, on soovitatav teha täielik vaktsineerimiskuur.
It is recommended that all patients be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating Entyvio therapy.
Kõikidel patsientidel on soovitatav vajalikud immuniseerimised teha enne ravi alustamist Entyvioga järgides kehtivaid immuniseerimisjuhiseid.
It is recommended that all patients receiving Caelyx routinely undergo frequent ECG monitoring.
Kõigil Caelyx’it saavatel patsientidel tuleb regulaarselt ja sageli teostada EKG-uuringut.
It is recommended that all patients, be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating RoActemra therapy.
Enne RoActemra-ravi alustamist on soovitatav teha kõikidele patsientidele kõik vaktsinatsioonid vastavalt kehtivatele juhistele.
It is recommended that all patients, including children, avoid exposure to direct sunlight during Voriconazole Accord treatment and use measures such as protective clothing and sunscreen with high sun protection factor (SPF).
Patsientidel, kaasa arvatud lapsed, soovitatakse ravi ajal Voriconazole Accord’iga vältida kokkupuudet otsese päikesevalgusega ning kasutada kaitseriietust ja päikesekaitsekreemi, millel on kõrge päikesekaitsefaktor (SPF).
It is recommended that all patients, including children, avoid exposure to direct sunlight during Voriconazole Hospira treatment and use measures such as protective clothing and sunscreen with high sun protection factor (SPF).
Patsientidel, kaasa arvatud lapsed, soovitatakse ravi ajal Voriconazole Hospira’ga vältida kokkupuudet otsese päikesevalgusega ning kasutada kaitseriietust ja päikesekaitsekreemi, millel on kõrge päikesekaitsefaktor (SPF, sun protection factor).
It is recommended that alternative administration forms should be considered for concomitant treatment of concurrent diseases that can be treated via nasal administration.
Ravi alustamisel Instanyliga tuleb muude kaasuvate haiguste tõttu intranasaalselt manustatavate ravimite korral kaaluda alternatiivse manustamisviisi võimalust.
It is recommended that Ambirix should be administered in settings where completion of the two-dose vaccination course can be assured.
Ambirix’i kasutamine on soovitatav tingimustes, kus saab tagada kahest annusest koosneva vaktsinatsioonikuuri lõpuleviimise.
It is recommended that AMMONAPS granules are used instead.
Tablettide asemel on soovitatav kasutada AMMONAPS’i graanuleid.
It is recommended that an intravenous antihistamine be administered 15-30 minutes before the infusion of Strimvelis.
15...30 minutit enne Strimvelis’e infusiooni on soovitatav manustada intravenoosset antihistamiinikumi.
It is recommended that animals are fasted for 12 hours prior to administration.
Soovitatav on hoida loomi söömata 12 tundi enne ravimi manustamist.
It is recommended that animals are fasted for 12 hours prior to Sedadex administration.
Soovitatav on loomi 12 tundi enne Sedadexi manustamist mitte sööta.
It is recommended that antihistamine medicinal product be repeated every 4–6 hours as required during infusion of Unituxin.
Antihistamiini manustamist soovitatakse Unituxini infusiooni ajal vastavalt vajadusele korrata iga 4...6 tunni järel.
It is recommended that any additional pathology be investigated and treated appropriately.
Mis tahes lisapatoloogiat on soovitatav uurida ning asjakohaselt ravida.
It is recommended that Atripla be taken on an empty stomach since food may increase efavirenz exposure and may lead to an increase in the frequency of adverse reactions (see sections 4.4 and 4.8).
Atripla’t soovitatakse manustada tühja kõhuga, sest koos toiduga manustamisel võib suureneda efavirensi ekspositsioon, mis võib viia kõrvaltoimete esinemissageduse suurenemiseni (vt lõigud 4.4 ja 4.8).
It is recommended that Atripla be taken on an empty stomach, preferably at bedtime.
Atriplat on soovitatav võtta tühja kõhuga, eelistatavalt enne magamaminekut.
It is recommended that Atripla be taken on an empty stomach, preferably at bedtime.
Atripla’t soovitatakse võtta tühja kõhuga, eelistatavalt magamaminekuajal.
It is recommended that blood pressure is measured periodically in patients over 65 years.
Nagu teiste antipsühhootikumide puhul, on üle 65-aastastel patsientidel soovitatav mõõta perioodiliselt vererõhku.
It is recommended that blood pressure is measured periodically in patients over 65 years.
Nii nagu teiste antipsühhootikumidega, soovitatakse ka Oolansapiini kasutamisel üle 65-aastastel patsientidel soovitatakse perioodiliselt vererõhku mõõta
It is recommended that blood pressure is measured periodically in patients over 65 years.
Nii nagu teiste antipsühhootikumidega, soovitatakse ka Oolansapiini kasutamisel üle 65-aastastel patsientidel soovitatakse perioodiliselt vererõhku mõõta.
It is recommended that both doses of Xyrem should be made up at the same time upon retiring to bed.
Soovitatav on, et Xyrem’i mõlemad annused võetakse ühel ajal enne voodisse minekut.
It is recommended that caffeine citrate administration should be stopped when the patient has 5-7 days without a significant apnoeic attack.
Kofeiintsitraadi manustamine on soovitatav lõpetada, kui patsiendil ei ole esinenud 5–7 päeva jooksul olulisi apnoehooge.
It is recommended that cats and ferrets living in, or travelling to, areas endemic for heartworm are treated monthly with the product to protect them from heartworm disease.
Kassidele ja tuhkrutele, kes elavad või reisivad piirkondades, kus on oht nakatuda südameussidega, on soovitatav manustada preparaati kord kuus, et kaitsta loomi nakatumise eest.
It is recommended that CellCept should not be administered concomitantly with azathioprine because such concomitant administration has not been studied.
CellCept’i ei ole soovitatav manustada koos asatiopriiniga, sest sellise kombinatsiooni kasutamist ei ole uuritud.
It is recommended that Cerezyme is used immediately after it has been mixed with sterile water.
Cerezyme’i on soovitatav kasutada vahetult pärast süsteveega segamist.
It is recommended that chemotherapy not be added to treatment with steroids since there is no experience with administration of both steroids and chemotherapy during treatment of the leukocyte activation syndrome due to TRISENOX.
Kemoteraapiat on soovitatav steroidravi ajal mitte lisada, kuna puudub kogemus steroidide ja kemoteraapia samaaegse kasutamise kohta TRISENOX’ist tingitud leukotsüütide aktivatsioonisündroomi ravi ajal.
It is recommended that children, if possible, be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating Humira therapy.
On soovitatav, et lastel teostatakse võimaluse korral kõik immuniseerimised vastavalt kehtivale immuniseerimise juhendile enne Humira’ga ravi alustamist.
It is recommended that Cinacalcet Mylan be taken with food or shortly after a meal, as studies have shown that bioavailability of cinacalcet is increased when taken with food (see section 5.2).
Cinacalcet Mylan’it on soovitav võtta koos toiduga või vahetult pärast söömist, sest uuringud on näidanud, et tsinakaltseedi biosaadavus suureneb võtmisel koos toiduga (vt lõik 5.2).
It is recommended that CKD patients not on dialysis are given vitamin D supplements (approximately 400 IU of native vitamin D daily) which can be part of a multivitamin preparation to be taken apart from their dose of Renvela.
Dialüüsi mittesaavatele kroonilise neeruhaigusega patsientidele on soovitatav määrata täiendavalt vitamiini D (ligikaudu 400 RÜ looduslikku vitamiini D päevas), mis võib olla osa multivitamiinpreparaadist, võetuna eraldi Renvela annusest.
It is recommended that CKD patients not on dialysis are given vitamin D supplements (approximately 400 IU of native vitamin D daily) which can be part of a multivitamin preparation to be taken apart from their dose of Sevelamer carbonate Zentiva.
Dialüüsi mittesaavatele kroonilise neeruhaigusega patsientidele on soovitatav määrata täiendavalt vitamiini D (ligikaudu 400 RÜ looduslikku vitamiini D päevas), mis võib olla osa multivitamiinpreparaadist, võetuna eraldi Sevelamer carbonate Zentiva annusest.
It is recommended that clinical and neurological examinations are performed in patients prior to starting thalidomide therapy, and that routine monitoring is carried out regularly during treatment.
Enne talidomiidravi alustamist soovitatakse kliinilist ja neuroloogilist läbivaatust ja ravi ajal on vajalik regulaarne kontroll.
It is recommended that Clomicalm be administered to dogs with cardiovascular dysfunction or epilepsy with caution and only after an assessment of the benefit risk ratio.
Kardiovaskulaarsüsteemi häiretega või epilepsiaga koertele on soovitav kasutada ettevaatusega ning ainult pärast riski ja kasulikkuse kaalumist.
It is recommended that concomitant use of nasal decongestants is avoided (see section 5.2)
Seetõttu on Instanyli kasutamisel soovitatav hoiduda intranasaalsete dekongestantide manustamisest (vt lõik 5.2).
It is recommended that consideration be given to concomitant PFMT.
Soovitav on kasutada samaaegselt VPLT-ga.
It is recommended that creatinine clearance is calculated in all patients prior to initiating therapy with Atripla and renal function (creatinine clearance and serum phosphate) is also monitored after two to four weeks of treatment, after three months of treatment and every three to six months thereafter in patients without renal risk factors.
Enne ravi alustamist Atripla’ga on soovitatav kõikidel patsientidel arvutada kreatiniini kliirens ja jälgida ka neerufunktsiooni (kreatiniini kliirensit ja seerumi fosfaadisisaldust) kahe kuni nelja ravinädala järel, kolme ravikuu järel ning edaspidi iga kolme kuni kuue kuu järel neerufunktsiooniga seotud riskifaktoriteta patsientidel.
It is recommended that creatinine clearance is calculated in all patients prior to initiating therapy with Eviplera and renal function (creatinine clearance and serum phosphate) is also monitored after two to four weeks of treatment, after three months of treatment and every three to six months thereafter in patients without renal risk factors.
Enne ravi alustamist Eviplera’ga on soovitatav kõikidel patsientidel arvutada kreatiniini kliirens ja jälgida ka neerufunktsiooni (kreatiniini kliirensit ja seerumi fosfaati) kahe kuni nelja ravinädala järel, kolme ravikuu järel ning edaspidi iga kolme kuni kuue kuu järel neerufunktsiooniga seotud riskifaktoriteta patsientidel.